演化之聲
THE SOUND OF EVOLUTION
Human Gene AtlasHOMO SAPIENS
HUMAN PROTEIN-CODING GENE

VCPIBMPFD

valosin containing protein

VCP(valosin containing protein)編碼 AAA ATPase 家族蛋白,參與膜運輸、蛋白質品質管制與細胞內蛋白質清除,也涉及細胞分裂及 DNA 損傷反應。

Homo sapiens9p13.3UniProt P55072
OFFICIAL SYMBOL
VCP
CHROMOSOME
9
UNIPROT
P55072
PDB / ALPHAFOLD
10QQ
01 / GENE OVERVIEW

基因總覽

VCP(valosin containing protein)是蛋白質編碼基因,其產物屬於 AAA ATPase 家族。蛋白質由 806 個胺基酸組成,並可組成六聚體;其環狀組裝與多種細胞內複合體的形成相關。C 端含有與 UBXN6 互作的區域及 PIM motif,部分區域則被註記為無序區。VCP 在細胞中扮演多面向角色,涵蓋膜與蛋白質的處理、細胞分裂及 DNA 損傷相關過程。

Official symbol
VCP
Gene name
valosin containing protein
Organism
Homo sapiens
Gene type
Protein coding
HGNC ID
HGNC:12666
UniProt
P55072
02 / NOMENCLATURE

基因異名與舊稱

Alternative gene names & synonyms
IBMPFDp97CDC48TERA

異名取自 HGNC,可能包含歷史名稱;蛋白質名稱以 UniProt 註解為準。

03 / GENOMIC CONTEXT

染色體位置與基因結構

Chromosome 99p13.3
chr9 · 138,394,717 bp · GRCh38chr9p24.3 · 1–2200000 · gnegchr9p24.2 · 2200001–4600000 · gpos25chr9p24.1 · 4600001–9000000 · gnegchr9p23 · 9000001–14200000 · gpos75chr9p22.3 · 14200001–16600000 · gnegchr9p22.2 · 16600001–18500000 · gpos25chr9p22.1 · 18500001–19900000 · gnegchr9p21.3 · 19900001–25600000 · gpos100chr9p21.2 · 25600001–28000000 · gnegchr9p21.1 · 28000001–33200000 · gpos100chr9p13.3 · 33200001–36300000 · gnegchr9p13.2 · 36300001–37900000 · gpos25chr9p13.1 · 37900001–39000000 · gnegchr9p12 · 39000001–40000000 · gpos50chr9p11.2 · 40000001–42200000 · gnegchr9p11.1 · 42200001–43000000 · acenchr9q11 · 43000001–45500000 · acenchr9q12 · 45500001–61500000 · gvarchr9q13 · 61500001–65000000 · gnegchr9q21.11 · 65000001–69300000 · gpos25chr9q21.12 · 69300001–71300000 · gnegchr9q21.13 · 71300001–76600000 · gpos50chr9q21.2 · 76600001–78500000 · gnegchr9q21.31 · 78500001–81500000 · gpos50chr9q21.32 · 81500001–84300000 · gnegchr9q21.33 · 84300001–87800000 · gpos50chr9q22.1 · 87800001–89200000 · gnegchr9q22.2 · 89200001–91200000 · gpos25chr9q22.31 · 91200001–93900000 · gnegchr9q22.32 · 93900001–96500000 · gpos25chr9q22.33 · 96500001–99800000 · gnegchr9q31.1 · 99800001–105400000 · gpos100chr9q31.2 · 105400001–108500000 · gnegchr9q31.3 · 108500001–112100000 · gpos25chr9q32 · 112100001–114900000 · gnegchr9q33.1 · 114900001–119800000 · gpos75chr9q33.2 · 119800001–123100000 · gnegchr9q33.3 · 123100001–127500000 · gpos25chr9q34.11 · 127500001–130600000 · gnegchr9q34.12 · 130600001–131100000 · gpos25chr9q34.13 · 131100001–133100000 · gnegchr9q34.2 · 133100001–134500000 · gpos25chr9q34.3 · 134500001–138394717 · gnegVCPpq1 bp138,394,717 bp
GRCh38 / 1-based inclusiveDirection: reverse strand (−)
Genomic coordinates
chr9:35,053,928–35,072,725
Gene span
18,798 bp
Strand
Reverse (−)
Gene assembly
GRCh38
查看實際轉錄本與 exon 註解
TranscriptGenomic coordinatesExons
ENST00000358901 ★35,056,064–35,072,62517
ENST0000067990235,053,928–35,072,67116
ENST0000067865035,055,357–35,072,56117
ENST0000067725735,055,357–35,072,67117
ENST0000044853035,055,357–35,072,66817
ENST0000068133535,055,357–35,072,67116
ENST0000041744835,055,357–35,072,20517
ENST0000067986235,055,357–35,072,61117
ENST0000085425435,055,357–35,072,67116
ENST0000085425535,055,357–35,072,67117
ENST0000085425635,055,357–35,072,67116
ENST0000094060735,055,357–35,072,67117

顯示 12/27 個蛋白質編碼轉錄本;canonical 優先。

帶型與著絲點依 Ensembl 座標繪製;核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置,細小區間加粗以利辨識;實際基因長度與 exon 見下方資料。

04 / BIOLOGICAL FUNCTION

分子功能與生物學過程

VCP 是 ATP 水解酶,將 ATP 與水轉換為 ADP、磷酸及氫離子。其重要作用之一,是協助處理錯誤摺疊或受損蛋白質:VCP 與 UFD1、NPLOC4 組成的複合體可辨識泛素化蛋白,將內質網中的錯誤摺疊蛋白移至細胞質,再由蛋白酶體降解。VCP 也參與內質網壓力誘發的預先品質管制,使新合成蛋白質進入內質網的轉位受到選擇性抑制,並改送至細胞質降解;此外,它參與受損粒線體外膜蛋白的逆向轉位與降解,以及含泛素自噬體的成熟和泛素化蛋白的自噬清除。

在膜與細胞器調節方面,VCP 參與內質網向高基氏體的膜運輸、過渡性內質網形成,以及有絲分裂期間高基氏體堆疊的分裂與分裂後重組。它也參與有絲分裂末期的紡錘體解聚及封閉核膜形成。VCP 所在的複合體可參與 HMGCR 的固醇介導泛素化與內質網相關降解(ERAD)末步;在皮質神經元中,VCP 也透過 STUB1-VCP-UBXN2A 複合體介導 CHRNA3 的 ERAD。對於壓力顆粒,VCP 可協助抽離 G3BP1;它也可能參與膜蛋白送往溶小體降解的泛素依賴性分選,尤其可能涉及 caveolins。

VCP 亦參與 DNA 損傷處理。它會以 RNF8 與 RNF168 依賴的方式被募集至 DNA 雙股斷裂處,並促進 TP53BP1 到達損傷位點。在 SPRTN 招募下,VCP 會到達停滯的複製叉,可能透過抽離 DNA polymerase eta(POLH),避免跨損傷合成過度並限制損傷誘發突變;它也與 SPRTN metalloprotease 共同參與 DNA 合成期間共價 DNA-蛋白質交聯的修復。面對複製壓力時,VCP 參與卸載泛素化 CMG helicase 複合體;它也能辨識泛素化 PARP1,促進被困於染色質的 PARP1 移除。

在免疫與訊號調節方面,當 RIGI 的 CARD 結構域帶有 Lys-63 連結的泛素時,VCP 與 RIGI 互作並招募 RNF125,促進 RIGI 泛素化及降解,因此負向調節 type I interferon 生成。VCP 也透過控制 IGF1R 的穩態表現,間接調節 insulin-like growth factor receptor 訊號;並可調節 RNF19A 的 E3 ubiquitin-protein ligase 活性。

05 / GENE REGULATION

Promoter 與基因調控

到

以 TSS = 0 為基準:負數為上游、正數為下游,包含起點與終點。每次最多取得 100,000 bp。

TSS: 35072625 · 負股
依所選 TSS 來源,取得指定上、下游範圍的基因組序列。
擷取區間依所選 TSS 計算;調控註解與實驗支持的 TSS 可在下方查閱。
>VCP ENST00000358901 GRCh38 chr9:35072525-35073625 strand=-1 5′→3′
相對 TSS:-1000 到 +100 bp;1101 bp
依轉錄本 TSS 擷取的基因組序列;TSS = 0,兩端包含,未驗證為 promoter
ATGAGTGGAGTTGGGTCTGAAGGGTGGTCTAGATAGGCCTCTCAGGACAAGGGCAGGTACCTGTTACTTA
GAGACAGGCAGGTTTCTCTCAGAGTAACTCTTCACTCCCTTCCTAATTCCAAATTCTAGAAATTCGACTC
GTCTTAGTCAAATGTGTCTGTGTGGGTACAGGGTGAAAGGTGAATTGAGTCAGCATATCACCAACAGCTG
CCTGTTGACTACTAACAGGGACCCCTGTTATTTGGGGCCCAAGGATTTTCAAGTCCCAGCATATGCAGTT
TTCTTGCTAATTTGGGTTCTACTGAATTGGCTGTGTGTTCTGTGGTTGCCCTTTGACTTCTCTGGATTTG
AGTGCCTTATTATAAGGTATTAATATTAATGACGGGAGGAAGAAAGGCACAAGCGCTGAGAAACTGCAAA
GGCTGTGGGATTGGGGTTACCAGAGGGTGCAGTGACAATGGGGTAGGAGTGGGGTGCTAGTCAGAAAGTT
CAGAGTAGGGGTGGTTGGAGGCAGCGTTGAGAAGGAGCAAGAAGTGTCAGGGTGGTGATGGCGTCTTAGA
AGATCTCCAGGTTTTGGGAGAAGATGGGTGTATGGGTTACCACAATAGGACTAGACTAATACAAGGGTTC
AGTCTATTGTGCCACGTTCTTCCAGGAGGATAAACTCCGGAGCCAATGAACTGGAGCCAAGTGGGAGAGT
CCGCCTCTAAGGGATTAAAGGGTCTCCTTTCACTAATCGATCTCGCCCTATTCCTTTCGTTGATTGGCTG
AGAATTCCAATCCGTCGAGGAAGCGTAGCGTTGCGGCCAATTGACGTGGCGTTACTAGGCGTGTCGCATC
ACTGAGGCGGGAGCCAGGCCGCAAGCGAATTTCCTGATTGGCTGTGATCTGCGGGTTGCTGGGGAGAGGC
GCGGAGAGGCGGGCGAGAGTCCGCAGGGCAGGCGCTGATTGGCTGAGGTGGGAGCAGCTTCCCTTCCGAT
GATTCGGCTCTTCTCGGCTCAGTCTCAGCGAAGCGTCTGCGACCGTCGTTTGAGTCGTCGCTGCCGCTGC
CGCTGCCACTGCCACTGCCACCTCGCGGATCAGGAGCCAGCGTTGTTCGCC
VCP 位於負股。上下游依轉錄方向計算,序列一律以該方向的 5′→3′ 顯示;負股會取得反向互補序列。
EPDnew 實驗支持 promoter/TSS · 1 筆
EPDnew IDTSS(1-based)股向來源顯示區間
VCP_1 ↗9:35,072,625負股35,072,615–35,072,674

EPDnew human v006 · UCSC hg38,GRCh38/hg38,透過 UCSC 取得。TSS 具有 CAGE/RAMPAGE 等實驗資料支持;任意擷取的上下游區間仍需另行判讀調控功能,不能視為整段皆經功能驗證。

EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0

查看已取得的調控/motif 註解

ENSR9_B8XWS · enhancer · 35070060–35070614 · regulatory

ENSR9_C5GZ2 · enhancer · 35070818–35072194 · regulatory

ENSR9_B8XX6 · promoter · 35072195–35073158 · regulatory

ENSR9_5B8PQB · CTCF_binding_site · 35072196–35072217 · regulatory

ENSR9_5B8PRX · CTCF_binding_site · 35072544–35072565 · regulatory

· motif · 35070232–35070246 · motif

· motif · 35070232–35070246 · motif

· motif · 35071036–35071051 · motif

· motif · 35071036–35071051 · motif

· motif · 35071754–35071763 · motif

· motif · 35071880–35071890 · motif

· motif · 35071927–35071940 · motif

· motif · 35071927–35071940 · motif

· motif · 35072198–35072214 · motif

· motif · 35072373–35072390 · motif

· motif · 35072382–35072397 · motif

· motif · 35072474–35072489 · motif

· motif · 35072546–35072562 · motif

· motif · 35072729–35072744 · motif

· motif · 35072747–35072758 · motif

· motif · 35073286–35073299 · motif

· motif · 35073298–35073313 · motif

· motif · 35073298–35073315 · motif

· motif · 35073443–35073456 · motif

目前未取得此類註解。
序列擷取依所選 TSS 與相對範圍計算;該區間的調控功能需參照相應的實驗證據。
06 / PROTEIN ANATOMY

蛋白質結構域與序列

參考蛋白質長度:806 aa

1 aa806 aa功能區域基序
依 P55072 的 UniProt 殘基座標與蛋白質長度繪製;結構域、DNA 結合區、功能區域與基序分列,重疊註解分行顯示。區域色彩區分類型,並非活性或信心分數。

VCP 蛋白長 806 個胺基酸,屬於 AAA ATPase 家族。第 708–727 位及 768–806 位胺基酸區段被註記為無序區;第 797–806 位區段參與與 UBXN6 的互作,末端第 802–806 位含有 PIM motif。

功能區域Disordered708–727 aa
功能區域Disordered768–806 aa
功能區域Interaction with UBXN6797–806 aa
基序PIM motif802–806 aa
07 / STRUCTURAL BIOLOGY

蛋白質三維結構

自動載入 · 可拖曳旋轉與縮放
正在載入 PDB · 10QQ…

PDB · 10QQ

EM · 2.13 A · A/B/C/D/E/F/G/H/I/J/K/L=1-806

查看原始結構紀錄 ↗

實驗模型;依序列位置著色,可能只覆蓋局部區域。

08 / SUBCELLULAR LOCALIZATION

細胞內定位

動物細胞結構與蛋白質定位細胞膜包圍細胞質;細胞核內有核仁,粗面內質網鄰接核膜,粒線體含內膜摺疊,高基氏體由堆疊扁平囊組成。深綠色圓點依來源註解標記定位,器官大小與數量為示意。圓點數量不表示含量;未繪示構造列於圖旁文字。 細胞質 細胞膜 粗面內質網與核糖體 細胞核與核膜 核仁 粒線體:外膜與含摺疊的內膜 高基氏體與運輸囊泡 胞內體、溶體與其他囊泡(示意)
定位:Cytoplasm, cytosol;Endoplasmic reticulum;Nucleus;Cytoplasm, Stress granule

VCP 可位於細胞質、細胞溶質、內質網、細胞核及壓力顆粒。 定位會隨情境改變:它可經 AMFR/gp78 招募至內質網細胞質側,也會在 DNA 雙股斷裂後到達損傷位置,或由 SPRTN 招募至停滯複製叉。 砷酸鹽誘發壓力時,VCP 與壓力顆粒共定位;受損且帶有 K48 連結泛素鏈的溶小體亦可募集 VCP。

深綠色圓點:來源記載的蛋白質定位;數量不表示含量。

動物細胞結構示意;器官大小與數量不按比例。點選細胞構造可查看定位註解。

09 / PROTEIN NETWORK

交互作用與訊號網絡

圖中 50 個夥伴 · 最多顯示 50 個
IBMPFDVCPAMFRASPSCR1ATG5ATXN1ATXN3CEP19CHEK2CNOT3CUL4ADTNBELAVL4EPSTI1FAF1FAF2FCHSD2GNAO1GRB2HSPB1HTTLNX1LZICMETTL17NOD2NPLOC4NSFL1CNTAQ1PLAAPPARAPPP1CAPSAPPSMA1PSMC1PTPN3RNF115RNF125RNF8RPL9P9SIK2SLC43A3SNRNP35STT3AUBE2D1UBE4BUBOX5UBXN1UBXN10UBXN11UBXN2AUBXN2BUBXN4
來源支持的結構/直接結合關係其他來源關係紀錄

拖曳節點後放開可帶動位置變化;點選夥伴查看證據。位置與連線長度不代表結合強度,圖中未推定夥伴彼此之間的關係。

更多交互作用夥伴 · 已取得 61 個夥伴
第 1 頁

查看 UniProt 完整互作來源 ↗

VCP 可形成具有六重徑向對稱的環狀同六聚體,直徑約 12.5 nm。它與 STX5A、NSFL1C 形成的複合體可結合富含磷脂醯乙醇胺的膜並促進高基氏體膜融合;NSFL1C 以同三聚體形式結合在 VCP 六聚體一端。NPLOC4-UFD1 異二聚體結合 VCP 後會抑制高基氏體膜融合,VCIP135 則可透過 VCP 的 ATP 水解促使複合體解離。VCP 另與 p37、SPRTN、AMFR/gp78、DERL 蛋白及多種 UBX domain-containing proteins 形成互作或複合體,參與膜融合、蛋白質逆向轉位與其他細胞功能。

10 / HUMAN HEALTH

疾病與遺傳關聯

VCP 變異與數種常染色體顯性疾病相關。IBMPFD1 可呈現顯著肌無力、符合 Paget disease 的溶骨性骨病灶,並可能有早發性額顳型失智;臨床特徵的外顯率不完全。FTDALS6 可於成年期出現額顳型失智或肌萎縮性側索硬化症,家族內表現差異大,部分患者同時具有兩者特徵。CMT2Y 則為軸突型周邊神經病變,特徵包括進行性無力與肌肉萎縮,通常先影響腓骨肌,之後涉及手臂遠端肌肉。這些疾病資料描述的是影響 VCP 基因的變異與疾病關聯。

個別變異的臨床意義取決於其證據;基因層級的疾病關聯不能套用至所有變異。
11 / CONTEXTUAL FUNCTIONAL EVIDENCE MATRIX

Contextual Functional Evidence Matrix

功能證據與細胞情境矩陣

矩陣以「功能主張」為列,以細胞情境、干預條件、量測結果與證據來源為欄,方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣;一般功能註解另列於下方。

7 筆功能證據/註解
目前尚無同時具備實驗情境與干預/量測資訊的證據列。可查核的功能敘述列於「功能註解總覽」,空白實驗欄位不以推測補齊。
功能註解總覽 · 7 筆
功能面向功能敘述證據類型可查核來源
功能VCP 參與內質網與高基氏體膜運輸、高基氏體在有絲分裂期間的分裂及分裂後重組,也協助泛素化錯誤摺疊蛋白由內質網移至細胞質降解。其作用並涵蓋蛋白質品質管制、自噬、壓力顆粒清除、DNA 損傷與複製叉處理、粒線體外膜蛋白清除,以及免疫與受體訊號調節;部分功能明確標示為可能參與。含實驗來源
證據與來源

Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and NPLOC4 binds ubiquitinated proteins and is necessary for the export of misfolded proteins from the ER to the cytoplasm, where they are degraded by the proteasome. The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. Regulates E3 ubiquitin-protein ligase activity of RNF19A. Component of the VCP/p97-AMFR/gp78 complex that participates in the final step of the sterol-mediated ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Mediates the endoplasmic reticulum-associated degradation of CHRNA3 in cortical neurons as part of the STUB1-VCP-UBXN2A complex. Involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation. Involved in clearance process by mediating G3BP1 extraction from stress granules. Also involved in DNA damage response: recruited to double-strand breaks (DSBs) sites in a RNF8- and RNF168-dependent manner and promotes the recruitment of TP53BP1 at DNA damage sites. Recruited to stalled replication forks by SPRTN: may act by mediating extraction of DNA polymerase eta (POLH) to prevent excessive translesion DNA synthesis and limit the incidence of mutations induced by DNA damage. Together with SPRTN metalloprotease, involved in the repair of covalent DNA-protein cross-links (DPCs) during DNA synthesis. Involved in interstrand cross-link repair in response to replication stress by mediating unloading of the ubiquitinated CMG helicase complex (By similarity). Mediates extraction of PARP1 trapped to chromatin: recognizes and binds ubiquitinated PARP1 and promotes its removal. Required for cytoplasmic retrotranslocation of stressed/damaged mitochondrial outer-membrane proteins and their subsequent proteasomal degradation. Essential for the maturation of ubiquitin-containing autophagosomes and the clearance of ubiquitinated protein by autophagy. Acts as a negative regulator of type I interferon production by interacting with RIGI: interaction takes place when RIGI is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of RIGI. May play a role in the ubiquitin-dependent sorting of membrane proteins to lysosomes where they undergo degradation. May more particularly play a role in caveolins sorting in cells. By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway

PMID 15456787 ↗ · PMID 16168377 ↗ · PMID 16186510 ↗ · PMID 20104022 ↗ · PMID 21118995 ↗ · PMID 21822278 ↗ · PMID 22020440 ↗ · PMID 22120668 ↗ · PMID 22607976 ↗ · PMID 23042605 ↗ · PMID 23042607 ↗ · PMID 23335559 ↗ · PMID 26265139 ↗ · PMID 26471729 ↗ · PMID 26565908 ↗ · PMID 26692333 ↗ · PMID 27753622 ↗ · PMID 29804830 ↗ · PMID 32152270 ↗ · PMID 34739333 ↗ · PMID 35013556 ↗ · PMID 38762759 ↗

開啟資料庫紀錄 ↗

分子活性ATP + H2O = ADP + phosphate + H(+)含實驗來源
證據與來源

ATP + H2O = ADP + phosphate + H(+)

PMID 26471729 ↗

開啟資料庫紀錄 ↗

交互作用VCP 形成具六重對稱的同六聚體環狀結構,並與多種蛋白質組成複合體。與 STX5A、NSFL1C 組成的複合體可促進高基氏體膜融合;NPLOC4-UFD1 結合則抑制該融合,VCIP135 可透過 VCP ATP 水解促使複合體解離。其他互作涉及蛋白質逆向轉位、ERAD、複製叉募集及自噬等功能。含實驗來源
證據與來源

Homohexamer. Forms a ring-shaped particle of 12.5 nm diameter, that displays 6-fold radial symmetry. Part of a ternary complex containing STX5A, NSFL1C and VCP. NSFL1C forms a homotrimer that binds to one end of a VCP homohexamer. The complex binds to membranes enriched in phosphatidylethanolamine-containing lipids and promotes Golgi membrane fusion. Binds to a heterodimer of NPLOC4 and UFD1, binding to this heterodimer inhibits Golgi-membrane fusion. Interaction with VCIP135 leads to dissociation of the complex via ATP hydrolysis by VCP. Part of a ternary complex containing NPLOC4, UFD1 and VCP. Interacts with NSFL1C-like protein p37; the complex has membrane fusion activity and is required for Golgi and endoplasmic reticulum biogenesis. Interacts with SELENOS and SYVN1, as well as with DERL1 (via SHP-box motif), DERL2 and DERL3; which probably transfer misfolded proteins from the ER to VCP. Interacts with SVIP and forms a complex with SVIP and DERL1. Component of a complex required to couple retrotranslocation, ubiquitination and deglycosylation composed of NGLY1, SAKS1, AMFR, VCP and RAD23B. Part of a complex composed of STUB1/CHIP, VCP/p97, CHRNA3, and UBXN2A that modulates the ubiquitination and endoplasmic reticulum-associated degradation (ERAD) of CHRNA3. Within the complex UBXN2A acts as a scaffold protein required for the interaction of CHRNA3 with VCP/p97, this interaction also inhibits CHRNA3 ubiquitination by STUB1/CHIP and subsequently ERAD. Interacts with UBXN2A (via UBX domain); the interaction is required for the interaction of CHRNA3 in the STUB1-VCP-UBXN2A complex. Directly interacts with UBXN4 and RNF19A. Interacts with CASR. Interacts with UBE4B and YOD1. Interacts with clathrin. Interacts with RNF103. Interacts with TRIM13 and TRIM21. Component of a VCP/p97-AMFR/gp78 complex that participates in the final step of the endoplasmic reticulum-associated degradation (ERAD) of HMGCR. Interacts directly with AMFR/gp78 (via its VIM). Interacts with RHBDD1 (via C-terminal domain). Interacts with SPRTN; leading to recruitment to stalled replication forks. Interacts with WASHC5. Interacts with UBOX5. Interacts (via N-terminus) with UBXN7, UBXN8, and probably several other UBX domain-containing proteins (via UBX domains); the interactions are mutually exclusive with VIM-dependent interactions such as those with AMFR and SELENOS. Forms a complex with UBQLN1 and UBXN4. Interacts (via the PIM motif) with RNF31 (via the PUB domain). Interacts with RIGI and RNF125; interaction takes place when RIGI is ubiquitinated via 'Lys-63'-linked ubiquitin on its CARD domains, leading to recruit RNF125 and promote ubiquitination and degradation of RIGI. Interacts with BAG6. Interacts with UBXN10. Interacts with UBXN6; the interaction with UBXN6 is direct and competitive with UFD1. Forms a ternary complex with CAV1 and UBXN6. Interacts with PLAA, UBXN6 and YOD1; may form a complex involved in macroautophagy. Interacts with ANKZF1. Interacts with ubiquitin-binding protein FAF1. Interacts with ZFAND2B (via VIM motif); the interaction is direct. Interacts with ZFAND1 (via its ubiquitin-like region); this interaction occurs in an arsenite-dependent manner. Interacts with CCDC47 (By similarity). Interacts with UBAC2 (By similarity). Interacts with LMBR1L. Interacts with ATXN3. Interacts with TEX264; bridging VCP to covalent DNA-protein cross-links (DPCs). Interacts with FBXL4

PMID 15215856 ↗ · PMID 15362974 ↗ · PMID 15456787 ↗ · PMID 16168377 ↗ · PMID 16186509 ↗ · PMID 16186510 ↗ · PMID 16289116 ↗ · PMID 16449189 ↗ · PMID 16513638 ↗ · PMID 16968747 ↗ · PMID 17314412 ↗ · PMID 17872946 ↗ · PMID 18022694 ↗ · PMID 18656546 ↗ · PMID 18675248 ↗ · PMID 19174149 ↗ · PMID 19275885 ↗ · PMID 19818707 ↗ · PMID 19822669 ↗ · PMID 19887378 ↗ · PMID 20512113 ↗ · PMID 20833645 ↗ · PMID 21636303 ↗ · PMID 21822278 ↗ · PMID 21914798 ↗ · PMID 21949850 ↗ · PMID 22120668 ↗ · PMID 22537386 ↗

開啟資料庫紀錄 ↗

細胞定位VCP 位於細胞質、細胞溶質、內質網、細胞核與壓力顆粒,也見於肌萎縮性側索硬化症患者運動神經元的神經元玻璃樣包涵體,以及帕金森病患者神經元的 Lewy bodies。它可依特定互作或細胞狀態被募集至內質網表面、DNA 損傷位點、停滯複製叉、受損溶小體及砷酸鹽誘發的壓力顆粒。含實驗來源
證據與來源

Cytoplasm, cytosol; Endoplasmic reticulum; Nucleus; Cytoplasm, Stress granule; Present in the neuronal hyaline inclusion bodies specifically found in motor neurons from amyotrophic lateral sclerosis patients. Present in the Lewy bodies specifically found in neurons from Parkinson disease patients. Recruited to the cytoplasmic surface of the endoplasmic reticulum via interaction with AMFR/gp78. Following DNA double-strand breaks, recruited to the sites of damage. Recruited to stalled replication forks via interaction with SPRTN. Recruited to damaged lysosomes decorated with K48-linked ubiquitin chains. Colocalizes with TIA1, ZFAND1 and G3BP1 in cytoplasmic stress granules (SGs) in response to arsenite-induced stress treatment

PMID 15456787 ↗ · PMID 15215856 ↗ · PMID 23042605 ↗ · PMID 26842564 ↗ · PMID 29804830 ↗

開啟資料庫紀錄 ↗

疾病關聯IBMPFD1 為常染色體顯性疾病,可有類似肢帶型肌肉失養症的致殘性肌無力、符合 Paget disease 的溶骨性骨病灶,以及早發性額顳型失智;臨床特徵的外顯率不完全。此疾病與影響 VCP 基因的變異相關。含實驗來源
證據與來源

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1 IBMPFD1 An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance. The disease is caused by variants affecting the gene represented in this entry MIM: 167320

PMID 15034582 ↗ · PMID 15732117 ↗ · PMID 16247064 ↗ · PMID 16321991 ↗ · PMID 17935506 ↗ · PMID 20104022 ↗ · PMID 20335036 ↗ · PMID 20512113 ↗ · PMID 21822278 ↗ · PMID 23349634 ↗ · PMID 25125609 ↗ · PMID 25878907 ↗ · PMID 27209344 ↗ · PMID 27753622 ↗ · PMID 29804830 ↗ · PMID 36980948 ↗

開啟資料庫紀錄 ↗

疾病關聯FTDALS6 是常染色體顯性神經退化疾病,可在成年期出現額顳型失智或肌萎縮性側索硬化症,家族內表現差異大,部分患者兼有兩者。額顳型失智涉及額葉及顳葉萎縮、神經元流失、膠質增生與失智,並可能造成社交、行為或語言功能漸進改變;肌萎縮性側索硬化症則涉及腦、腦幹及脊髓運動神經元死亡,可導致致命性癱瘓。疾病與影響 VCP 的變異相關。含實驗來源
證據與來源

Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 FTDALS6 A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS6 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. Some patients with the disorder may have features of both diseases. The disease is caused by variants affecting the gene represented in this entry MIM: 613954

PMID 21145000 ↗ · PMID 23349634 ↗

開啟資料庫紀錄 ↗

疾病關聯CMT2Y 是常染色體顯性軸突型 Charcot-Marie-Tooth disease,屬周邊神經系統疾病,呈現進行性無力與萎縮,通常先影響腓骨肌,後續涉及手臂遠端肌肉。CMT2 類型以軸突退化為特徵,沒有明顯髓鞘變化,神經傳導速度正常或略降;此疾病與影響 VCP 基因的變異相關。含實驗來源
證據與來源

Charcot-Marie-Tooth disease, axonal, type 2Y CMT2Y An autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. The disease is caused by variants affecting the gene represented in this entry MIM: 616687

PMID 25125609 ↗ · PMID 25878907 ↗

開啟資料庫紀錄 ↗

情境矩陣 0 筆 · 一般功能註解 7 筆。互作清單與機器格式紀錄不列入本區。
證據分項判讀,不加總為單一可信度分數。「含實驗來源」依資料庫證據標記辨識;未逐篇核對原始方法的紀錄,不宣稱已完成實驗審查。
12 / SEQUENCE EXPLORER

核酸與蛋白質序列

完整轉錄本 · UTR / CDS 著色 · FASTA
ENST00000358901 · 3,746 nt · GRCh38
依 Ensembl exon 註解拼接的 GRCh38 參考序列,保留非編碼區。
1AGTCTCAGCGAAGCGTCTGCGACCGTCGTTTGAGTCGTCG40
41CTGCCGCTGCCGCTGCCACTGCCACTGCCACCTCGCGGAT80
81CAGGAGCCAGCGTTGTTCGCCCGACGCCTCGCTGCCGGTG120
121GGAGGAAGCGAGAGGGAAGCCGCTTGCGGGTTTGTCGCCG160
161CTGCTCGCCCACCGCCTGGAAGAGCCGAGCCCCGGCCCAG200
201TCGGTCGCTTGCCACCGCTCGTAGCCGTTACCCGCGGGCC240
241GCCACAGCCGCCGGCCGGGAGAGGCGCGCGCCATGGCTTC280
281TGGAGCCGATTCAAAAGGTGATGACCTATCAACAGCCATT320
321CTCAAACAGAAGAACCGTCCCAATCGGTTAATTGTTGATG360
361AAGCCATCAATGAGGACAACAGTGTGGTGTCCTTGTCCCA400
401GCCCAAGATGGATGAATTGCAGTTGTTCCGAGGTGACACA440
441GTGTTGCTGAAAGGAAAGAAGAGACGAGAAGCTGTTTGCA480
481TCGTCCTTTCTGATGATACTTGTTCTGATGAGAAGATTCG520
521GATGAATAGAGTTGTTCGGAATAACCTTCGTGTACGCCTA560
561GGGGATGTCATCAGCATCCAGCCATGCCCTGATGTGAAGT600
601ACGGCAAACGTATCCATGTGCTGCCCATTGATGACACAGT640
641GGAAGGCATTACTGGTAATCTCTTCGAGGTATACCTTAAG680
681CCGTACTTCCTGGAAGCGTATCGACCCATCCGGAAAGGAG720
721ACATTTTTCTTGTCCGTGGTGGGATGCGTGCTGTGGAGTT760
761CAAAGTGGTGGAAACAGATCCTAGCCCTTATTGCATTGTT800
801GCTCCAGACACAGTGATCCACTGCGAAGGGGAGCCTATCA840
841AACGAGAGGATGAGGAAGAGTCCTTGAATGAAGTAGGGTA880
881TGATGACATTGGTGGCTGCAGGAAGCAGCTAGCTCAGATA920
921AAGGAGATGGTGGAACTGCCCCTGAGACATCCTGCCCTCT960

cDNA 使用 DNA 字母 T;mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區,未另外加入 poly(A) 尾;非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽,可複製或下載完整轉錄本與蛋白質;基因組 DNA 隨捲動取得所需範圍。